Attention to Licensed companies regarding the Reference Based Drug Price List

Purpose:

The purpose of this update is to inform pharmaceutical companies that the Reference-Based Medication Price List 2025 will be revised and published on the official website of Akılcı İlaç Kullanımı Dairesi Başkanlığı (Intelligent Medication Use Directorship). The list will include all medication products, and companies are required to submit their applications for inclusion in the list using a specific application form.

Effects on Industry:

The revision of the Reference-Based Medication Price List 2025 is expected to have significant effects on the pharmaceutical industry. Companies that produce and sell medications will need to adjust their pricing strategies to comply with the new list, which may lead to changes in medication availability, pricing, and sales revenue. The update may also impact healthcare providers and patients, who will need to adapt to the revised prices and potential changes in medication coverage.

Relevant Stakeholders:

The following stakeholders are affected by this update:

• Pharmaceutical companies that produce and sell medications
• Healthcare providers (hospitals, clinics, etc.) that purchase and prescribe medications
• Patients who rely on medications for their healthcare needs

These stakeholders will need to be aware of the revised prices and any changes in medication coverage, which may impact their business operations or individual health outcomes.

Next Steps:

Companies that want to have their products included in the Reference-Based Medication Price List 2025 must submit their applications between February 10th and 14th, 2025. The application form requires a signed declaration from the company’s authorized representative, confirming their consent for the sharing of relevant data with the public. Failure to comply with this deadline may result in exclusion from the list.

Any Other Relevant Information:

It is worth noting that the revision of the Reference-Based Medication Price List 2025 is part of a broader effort to ensure transparency and fairness in medication pricing. The update reflects the government’s commitment to promoting rational use of medications and ensuring access to affordable healthcare for all citizens.